(38) showed that the oral intervention with Theracurmin® in patients with impaired glucose tolerance or non-insulin-dependent diabetes mellitus could increase adiponectin expression, resulting in antiatherosclerotic action. The gene discussed is ADIPOQ; the disease is diabetes mellitus.